Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

1407 results about "Neurological disorder" patented technology

A type of nervous system disorder that affects brain and neurons.

Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto

Disclosed are devices and methods for detecting, preventing, and/or treating neurological disorders. These devices and methods utilize electrical stimulation, and comprise a unique concentric ring electrode component. The disclosed methods involve the positioning of multiple electrodes on the scalp of a mammal; monitoring the mammal's brain electrical patterns to identify the onset of a neurological event; identifying the location of the brain electrical patterns indicative of neurological event; and applying transcutaneous or transcranial electrical stimulation to the location of the neurological event to beneficially modify brain electrical patterns. The disclosed methods may be useful in the detection, prevention, and/or treatment of a variety of indications, such as epilepsy, Parkinson's Disease, Huntington's disease, Alzheimer's disease, depression, bipolar disorder, phobia, schizophrenia, multiple personality disorder, migraine or headache, concussion, attention deficit hyperactivity disorder, eating disorder, substance abuse, and anxiety. The disclosed methods may also be used in combination with other peripheral stimulation techniques.
Owner:LOUISIANA TECH UNIV RES FOUND A DIV OF LOUISIANA TECH UNIV FOUND +1

Composition and methods for treatment of neurological disorders and neurodegenerative diseases

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
Owner:MASSACHUSETTS INST OF TECH

Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

It has been discovered that the stimulation of beta -adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta -adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta -adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta -adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
Owner:MASSACHUSETTS INST OF TECH

Method and apparatus for detecting eye movement

InactiveUS6231187B1Simple and inexpensive and portableDiagnosing neurological disordersSensorsEye diagnosticsVisual field lossNeurological disorder
An apparatus for diagnosing or treating a neurological disorder, usually associated with a lack of attentiveness, in a subject by detecting the subject's eye movement. The apparatus includes a helmet for blocking visual stimuli from the subject's visual field; at least three visual cues disposed inside the helmet within the visual field of the subject when the helmet is placed on the subject's head, the visual cues capable of being switched from on to off states; at least two electrodes for attaching to the subject's face, the electrodes producing electrical signals corresponding to the subject's eye movements; signal processing means for controlling on and off states of the visual cues, receiving and processing electrical signals produced by the electrodes, and producing output signals corresponding to the subject's eye movements; and means for displaying output signals produced by the signal processing means. Methods are provided for diagnosing and treating a neurological disorder in a subject, using an apparatus according to the invention, comprising determining, in accordance with a selected test, whether the direction of the subject's eye movement in response to the switching on of either the left or the right visual cue is correct. After a prescribed number of trials, a score corresponding to the total number of correct eye movements is obtained, wherein the score is diagnostic of the neurological disorder. Treatment involves providing appropriate reinforcement in response to correct and/or incorrect eye movements.
Owner:QUEENS UNIV OF KINGSTON
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products